GE HealthCare Technologies Inc. Common Stock vs Teradyne, Inc. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.97 (market cap $31.07B), while Teradyne, Inc. trades at $349.01 (market cap $59.45B). The key difference: Teradyne, Inc. is the larger of the two by market cap, and GE HealthCare Technologies Inc. Common Stock pays the higher dividend (0.23%). Which is the better fit depends on your goals.
| GEHC | TER | |
|---|---|---|
Market Cap | $31.07B | $59.45B |
Volume | 3,443,020 | 2,735,541 |
Sector | Health | Technology |
52-Week High | $88.16 | $483.84 |
52-Week Low | $59.48 | $138.09 |
Enterprise Value | $39.53B | $59.20B |
Dividend Yield | 0.23% | 0.14% |
Typical Hold Time | — | 37 Days |
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Teradyne (TER) trades at $359.44, down 6.36% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a 25.77% net income margin and consistent earnings beats in recent quarters. Recent news highlights expansion in AI-driven test equipment, including the Magnum E2 and Iris 100 platforms, targeting growth in semiconductor and data center markets. Analyst consensus remains bullish with a $461.50 price target, though technical indicators suggest near-term caution.
Outlook is positive due to robust profitability and AI-related demand, but risks include competitive pressures and market volatility. The stock offers growth potential if execution aligns with analyst expectations, though investors should monitor earnings consistency and industry trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →